SCHEMBL167934

SCHEMBL167934

[CH2]C(C(=O)OC)C(=O)OC

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.48
CA14 Q9ULX7 2/20 0.40
ALDH1A1 P00352 3/20 0.39
KMT2A Q03164 3/20 0.37
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
TSHR P16473 2/20 0.33
KEAP1 Q14145 1/20 0.33
NFE2L2 Q16236 1/20 0.33
HCAR2 Q8TDS4 1/20 0.33
ZDHHC7 Q9NXF8 1/20 0.33
MEN1 O00255 1/20 0.31
MGAM O43451 1/20 0.30
GAA P10253 1/20 0.30
SI P14410 1/20 0.30
MGAM2 Q2M2H8 1/20 0.30
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7825027 0.85
SCHEMBL2654704 0.83 DGAT1 (0.41) SMN1; SMN2CA14KMT2ACA12CA1
SCHEMBL20657106 0.79
SCHEMBL1098657 0.78
SCHEMBL127462 0.78
SCHEMBL1097587 0.78
SCHEMBL16196001 0.78
SCHEMBL5664686 0.78
SCHEMBL344666 0.75
SCHEMBL7661704 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1725534-A1 NOVEL AMIDO-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS Altana Pharma AG (DE) 2006-11-29 EP claimed
WO-2005087745-A1 NOVEL AMIDO-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS ALTANA PHARMA AG (DE) 2005-09-22 WO claimed
EP-0791016-A1 POLYMER SYNTHESIS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1997-08-27 EP claimed
EP-4381345-A1 SWITCHING LAYERS FOR USE IN A WINDOW ELEMENT Merck Patent GmbH (DE) 2024-06-12 EP disclosed
EP-3704176-B1 ORGANIC SEMICONDUCTING COMPOUNDS RAYNERGY TEK INC (TW) 2024-05-15 EP disclosed
US-20240134218-A1 DEVICE FOR THE REGULATION OF LIGHT TRANSMISSION MERCK PATENT GMBH (DE) 2024-04-25 US disclosed
US-11958819-B2 Compounds for optically active devices Johnson & Johnson Surgical Vision, Inc. (US) 2024-04-16 US disclosed
US-11952528-B2 Switching layers for use in a switching element MERCK PATENT GMBH (DE) 2024-04-09 US disclosed
EP-3794650-B1 ORGANIC SEMICONDUCTORS RAYNERGY TEK INC (TW) 2024-03-13 EP disclosed
WO-2024012851-A1 SUSTAINABLE ANTIOXIDANT COMPOSITION, USE THEREOF AND POLYMER COMPOSITION COMPRISING THE SAME BASF SE (DE) 2024-01-18 WO disclosed
US-11839155-B2 Organic semiconducting compounds RAYNERGY TEK INC. (TW) 2023-12-05 US disclosed
EP-0381728-A1 DIFLUOROMETHYL COMPOUNDS. MERCK PATENT GMBH (DE) 1990-08-16 EP disclosed
EP-0367771-A1 ARYL SULPHUR PENTAFLUORIDES. MERCK PATENT GMBH (DE) 1990-05-16 EP disclosed
US-4925590-A Derivatives of 4-cyano-2,3-difluorophenol MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1990-05-15 US disclosed
WO-1990001056-A1 DIFLUOROMETHYL COMPOUNDS MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 1990-02-08 WO disclosed
WO-1989002425-A1 FLUORINATED OLIGOPHENYLS AND THEIR USE IN LIQUID CRYSTAL MATERIALS MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 1989-03-23 WO disclosed
WO-1988010251-A1 ARYL SULPHUR PENTAFLUORIDES MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 1988-12-29 WO disclosed
US-4735959-A HYPOGLYCEMIC AGENTS DR. KARL THOMAE GMBH (DE) 1988-04-05 US disclosed
EP-0099017-B1 PHENYL-ACETIC-ACID DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSTIONS CONTAINING THEM Dr. Karl Thomae GmbH (DE) 1988-03-02 EP disclosed
EP-0099017-A2 Phenyl-acetic-acid derivatives, their preparation and pharmaceutical compostions containing them Dr. Karl Thomae GmbH (DE) 1984-01-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11839155-B2 Organic semiconducting compounds OCIAD2, OCIAD1, OSTC SMN1; SMN2 3662/4885CA14 2127/4885ALDH1A1 2672/4885
US-11958819-B2 Compounds for optically active devices PDE6C, ALDH1A2, PDE6A SMN1; SMN2 4580/4885CA14 3995/4885ALDH1A1 199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.